← Leaderboards
Michel C Nussenzweig
California Institute Of Technology
$48,766,293
Attributed
$52,850,673
Total exposure
32
Grants
28
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $13.9M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$117,578,571 · 36
By mechanism
P01$84,463,002 · 16
R01$14,087,874 · 4
R37$5,361,249 · 1
U19$5,324,984 · 2
T32$3,001,700 · 1
UM1$2,948,452 · 1
Top collaborators
- Pamela J Bjorkman15 shared
- Jeffrey Victor Ravetch10 shared
- Marina Caskey3 shared
- Paul D Bieniasz2 shared
- Beatrice H Hahn2 shared
- Theodora Hatziioannou2 shared
- Charles M. Rice2 shared
- R. Brad Jones1 shared
Most similar at California Institute Of Technology
Same institution · by research overlap
- Dianne K Newman$9,370,026
- Pamela J Bjorkman$57,868,021
Others in their field
Top investigators on “Antibodies”
- Lawrence Corey · Fred Hutchinson Cancer Center$525,765,536
- Bambra Strokes · Ppd Development Lp$461,655,950
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$385,009,925
- Barton F Haynes · Duke University$372,611,596
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$323,573,074
- Dennis R. Burton · Scripps Research Institute$306,733,901
Research focus
AntibodiesCellsAntigensIn VivoGenesB-LymphocytesVaccinesBaseDesignProteinsPreventResponseLaboratoriesSerumInfectionExperimental StudyVirusNeutralizing AntibodyAffinityIn VitroCollaborationsImmunityResearch StudyVaccination
Grant awards (174)
Developing Immunogens to Elicit Broadly Neutralizing anti-HIV-1 Antibodies$4,026,004
P01 · FY2025 · AI
INSPIRE: Innovative Strategies for Personalized Immunotherapies and Reservoir Eradication$2,948,452
UM1 · FY2025 · AI
Immunity and Infectious Disease$299,406
T32 · FY2025 · AI · contact PI
Developing Immunogens to Elicit Broadly Neutralizing anti-HIV-1 Antibodies$4,197,323
P01 · FY2024 · AI
Broad neutralization of pandemic threat coronaviruses$4,259,011
P01 · FY2023 · AI
Developing Immunogens to Elicit Broadly Neutralizing anti-HIV-1 Antibodies$2,208,763
P01 · FY2023 · AI
The longevity and nature of the anti-SARS-CoV-2 cellular and humoral immune responses$983,100
P01 · FY2023 · AI · contact PI
Understanding B cell memory in response to diverse virus infections$555,183
U19 · FY2023 · AI · contact PI
Activation of HIV-1 specific B cell precursors using novel vaccine approaches$508,500
P01 · FY2023 · AI · contact PI
Class Switch Recombination in B Lymphocytes$423,750
R37 · FY2023 · AI · contact PI
Immunity and Infectious Disease$210,981
T32 · FY2023 · AI · contact PI
Broad neutralization of pandemic threat coronaviruses$6,423,268
P01 · FY2022 · AI
Developing Immunogens to Elicit Broadly Neutralizing anti-HIV-1 Antibodies$2,654,146
P01 · FY2022 · AI
The longevity and nature of the anti-SARS-CoV-2 cellular and humoral immune responses$1,454,501
P01 · FY2022 · AI · contact PI
Epitope-focused vaccine strategies against Zika virus$1,347,756
P01 · FY2022 · AI · contact PI
Project 1$588,940
P01 · FY2022 · AI · contact PI
Class Switch Recombination in B Lymphocytes$423,750
R37 · FY2022 · AI · contact PI
Understanding B cell memory in response to diverse virus infections$417,499
U19 · FY2022 · AI · contact PI
Activation of HIV-1 specific B cell precursors using novel vaccine approaches$280,199
P01 · FY2022 · AI · contact PI
Immunity and Infectious Disease$207,144
T32 · FY2022 · AI · contact PI
Activation of HIV-1 specific B cell precursors using novel vaccine approaches$117,329
P01 · FY2022 · AI · contact PI
Admin Core$29,861
P01 · FY2022 · AI · contact PI
Developing Immunogens to Elicit Broadly Neutralizing anti-HIV-1 Antibodies$2,619,302
P01 · FY2021 · AI
Epitope-focused vaccine strategies against Zika virus$1,347,756
P01 · FY2021 · AI · contact PI
Optimization of Fc effector activity of anti-HIV antibodies to target HIV reservoir$847,498
R01 · FY2021 · AI
Understanding B cell memory in response to diverse virus infections$554,702
U19 · FY2021 · AI · contact PI
Activation of HIV-1 specific B cell precursors using novel vaccine approaches$508,500
P01 · FY2021 · AI · contact PI
Project 1$508,499
P01 · FY2021 · AI · contact PI
Human monoclonal antibodies for prophylaxis and therapy against the new coronavirus$458,301
P01 · FY2021 · AI · contact PI
Class Switch Recombination in B Lymphocytes$423,750
R37 · FY2021 · AI · contact PI
Immunity and Infectious Disease$194,190
T32 · FY2021 · AI · contact PI
Enhancement of the HIV Antibody Database tool for Open Science$139,981
P01 · FY2021 · AI
Admin Core$33,900
P01 · FY2021 · AI · contact PI
Developing Immunogens to Elicit Broadly Neutralizing anti-HIV-1 Antibodies$2,711,483
P01 · FY2020 · AI
Epitope-focused vaccine strategies against Zika virus$1,347,756
P01 · FY2020 · AI · contact PI
Optimization of Fc effector activity of anti-HIV antibodies to target HIV reservoir$847,498
R01 · FY2020 · AI
Project 1$816,691
P01 · FY2020 · AI · contact PI
Epitope-focused vaccine strategies against Zika virus$816,691
P01 · FY2020 · AI · contact PI
Understanding B cell memory in response to diverse virus infections$554,701
U19 · FY2020 · AI · contact PI
Activation of HIV-1 specific B cell precursors using novel vaccine approaches$508,500
P01 · FY2020 · AI · contact PI
Project 1$508,500
P01 · FY2020 · AI · contact PI
Class Switch Recombination in B Lymphocytes$423,750
R37 · FY2020 · AI · contact PI
Human monoclonal antibodies for prophylaxis and therapy against the new coronavirus$400,050
P01 · FY2020 · AI · contact PI
Immunity and Infectious Disease$193,694
T32 · FY2020 · AI · contact PI
Admin Core$33,900
P01 · FY2020 · AI · contact PI
Developing Immunogens to Elicit Broadly Neutralizing anti-HIV-1 Antibodies$2,561,973
P01 · FY2019 · AI
Epitope-focused vaccine strategies against Zika virus$1,347,756
P01 · FY2019 · AI · contact PI
Optimization of Fc effector activity of anti-HIV antibodies to target HIV reservoir$847,498
R01 · FY2019 · AI
Understanding B cell memory in response to diverse virus infections$554,521
U19 · FY2019 · AI · contact PI
Activation of HIV-1 specific B cell precursors using novel vaccine approaches$527,499
P01 · FY2019 · AI · contact PI
Project 1$508,500
P01 · FY2019 · AI · contact PI
Class Switch Recombination in B Lymphocytes$423,750
R37 · FY2019 · AI · contact PI
Immunity and Infectious Disease$191,848
T32 · FY2019 · AI · contact PI
Admin Core$33,900
P01 · FY2019 · AI · contact PI
Epitope-focused vaccine strategies against Zika virus$1,365,131
P01 · FY2018 · AI · contact PI
Class Switch Recombination in B Lymphocytes$847,500
R37 · FY2018 · AI · contact PI
Optimization of Fc effector activity of anti-HIV antibodies to target HIV reservoir$847,498
R01 · FY2018 · AI
Modulation of Human Dendritic Cell Development by Adjuvants and Vaccines$529,025
U19 · FY2018 · AI · contact PI
Project 1$508,500
P01 · FY2018 · AI · contact PI
Admin Core$33,900
P01 · FY2018 · AI · contact PI
Development Structure and Function of Broadly Neutralizing anti-HIV Antibodies$2,100,311
P01 · FY2017 · AI
Class Switch Recombination in B Lymphocytes$1,123,749
R37 · FY2017 · AI · contact PI
Optimization of Fc effector activity of anti-HIV antibodies to target HIV reservoir$847,498
R01 · FY2017 · AI
Modulation of Human Dendritic Cell Development by Adjuvants and Vaccines$502,919
U19 · FY2017 · AI · contact PI
Animal Services$291,684
P01 · FY2017 · AI · contact PI
Human Antibodies to HIV$271,200
P01 · FY2017 · AI · contact PI
Immunity and Infectious Disease$189,470
T32 · FY2017 · AI · contact PI
Development Structure and Function of Broadly Neutralizing anti-HIV Antibodies$4,894,251
P01 · FY2016 · AI
Human Antibodies to HIV$836,099
P01 · FY2016 · AI · contact PI
Modulation of Human Dendritic Cell Development by Adjuvants and Vaccines$550,449
U19 · FY2016 · AI · contact PI
Class Switch Recombination in B Lymphocytes$423,750
R37 · FY2016 · AI · contact PI
Cellular dynamics in germinal centers during vaccination$408,831
R01 · FY2016 · AI · contact PI
Animal Services$360,609
P01 · FY2016 · AI · contact PI
Immunity and Infectious Disease$187,082
T32 · FY2016 · AI · contact PI
Development Structure and Function of Broadly Neutralizing anti-HIV Antibodies$2,100,313
P01 · FY2015 · AI
Modulation of Human Dendritic Cell Development by Adjuvants and Vaccines$555,535
U19 · FY2015 · AI · contact PI
Class Switch Recombination in B Lymphocytes$423,750
R37 · FY2015 · AI · contact PI
Human Antibodies to HIV$414,433
P01 · FY2015 · AI · contact PI
Cellular dynamics in germinal centers during vaccination$412,585
R01 · FY2015 · AI · contact PI
Animal Services$265,208
P01 · FY2015 · AI · contact PI
Immunity and Infectious Disease$177,898
T32 · FY2015 · AI · contact PI
Development Structure and Function of Broadly Neutralizing anti-HIV Antibodies$2,636,665
P01 · FY2014 · AI
Modulation of Human Dendritic Cell Development by Adjuvants and Vaccines$550,450
U19 · FY2014 · AI · contact PI
Class Switch Recombination in B Lymphocytes$423,750
R37 · FY2014 · AI · contact PI
Cellular dynamics in germinal centers during vaccination$416,230
R01 · FY2014 · AI · contact PI
Animal Services$362,222
P01 · FY2014 · AI · contact PI
Human Antibodies to HIV$336,786
P01 · FY2014 · AI · contact PI
Immunity and Infectious Disease$171,963
T32 · FY2014 · AI · contact PI
Development Structure and Function of Broadly Neutralizing anti-HIV Antibodies$2,123,313
P01 · FY2013 · AI
Novel approaches for vaccine design$1,696,945
P01 · FY2013 · AI · contact PI
Broadly neutralizing to HIV$397,600
P01 · FY2013 · AI · contact PI
Cellular dynamics in germinal centers during vaccination$394,580
R01 · FY2013 · AI · contact PI
Animal Services$335,980
P01 · FY2013 · AI · contact PI
Human Antibodies to HIV$312,385
P01 · FY2013 · AI · contact PI
Protein Expression Core$203,688
P01 · FY2013 · AI · contact PI
Immunity and Infectious Disease$181,642
T32 · FY2013 · AI · contact PI
FACS Core$140,565
P01 · FY2013 · AI · contact PI
Administrative$52,559
P01 · FY2013 · AI · contact PI
Novel approaches for vaccine design$1,805,259
P01 · FY2012 · AI · contact PI
Cellular dynamics in germinal centers during vaccination$440,578
R01 · FY2012 · AI · contact PI
Broadly neutralizing to HIV$422,978
P01 · FY2012 · AI · contact PI
Class Switch Recombination in B Lymphocytes$419,513
R01 · FY2012 · AI · contact PI
Protein Expression Core$216,691
P01 · FY2012 · AI · contact PI
Immunity and Infectious Disease$179,411
T32 · FY2012 · AI · contact PI
FACS Core$149,539
P01 · FY2012 · AI · contact PI
Administrative$55,913
P01 · FY2012 · AI · contact PI
Novel approaches for vaccine design$1,805,982
P01 · FY2011 · AI · contact PI
Cellular dynamics in germinal centers during vaccination$444,305
R01 · FY2011 · AI · contact PI
Class Switch Recombination in B Lymphocytes$419,513
R01 · FY2011 · AI · contact PI
Broadly neutralizing to HIV$377,220
P01 · FY2011 · AI · contact PI
Targeting Dendritic cells for immune tolerance$357,152
P01 · FY2011 · AI · contact PI
Protein Expression Core$250,547
P01 · FY2011 · AI · contact PI
Protein Expression$221,862
P01 · FY2011 · AI · contact PI
FACS Core$209,330
P01 · FY2011 · AI · contact PI
Immunity and Infectious Disease$173,829
T32 · FY2011 · AI · contact PI
Administrative$152,273
P01 · FY2011 · AI · contact PI
IDENTIFICATION OF HIV REACTIVE ANTIBODIES$84,020
P41 · FY2011 · RR · contact PI
ON THE ROLE OF 53BP1 IN PROTECTING DNA ENDS DURING REPAIR$10,429
P41 · FY2011 · RR · contact PI
ACTIVATION INDUCED DEAMINASE (AID) INTERACTING PROTEINS$1,384
P41 · FY2011 · RR · contact PI
Novel approaches for vaccine design$1,791,237
P01 · FY2010 · AI · contact PI
Novel approaches for vaccine design$1,763,339
P01 · FY2010 · AI · contact PI
Human Antibody Tolerance in Normal and SLE$456,909
P50 · FY2010 · AR · contact PI
Cellular dynamics in germinal centers during vaccination$448,871
R01 · FY2010 · AI · contact PI
Class Switch Recombination in B Lymphocytes$422,500
R01 · FY2010 · AI · contact PI
Broadly neutralizing to HIV$373,589
P01 · FY2010 · AI · contact PI
Targeting Dendritic cells for immune tolerance$350,463
P01 · FY2010 · AI · contact PI
Protein Expression Core$248,223
P01 · FY2010 · AI · contact PI
Protein Expression$217,786
P01 · FY2010 · AI · contact PI
FACS Core$207,434
P01 · FY2010 · AI · contact PI
Immunity and Infectious Disease$177,962
T32 · FY2010 · AI · contact PI
Administrative$150,964
P01 · FY2010 · AI · contact PI
IDENTIFICATION OF HIV REACTIVE ANTIBODIES$67,874
P41 · FY2010 · RR · contact PI
ACTIVATION INDUCED DEAMINASE (AID) INTERACTING PROTEINS$2,321
P41 · FY2010 · RR · contact PI
Novel approaches for vaccine design$1,777,832
P01 · FY2009 · AI · contact PI
Human Antibody Tolerance in Normal and SLE$520,147
P50 · FY2009 · AR · contact PI
Cellular dynamics in germinal centers during vaccination$440,295
R01 · FY2009 · AI · contact PI
Class Switch Recombination in B Lymphocytes$422,500
R01 · FY2009 · AI · contact PI
Targeting Dendritic cells for immune tolerance$374,806
P01 · FY2009 · AI · contact PI
Broadly neutralizing to HIV$369,515
P01 · FY2009 · AI · contact PI
Protein Expression Core$246,571
P01 · FY2009 · AI · contact PI
Protein Expression$233,011
P01 · FY2009 · AI · contact PI
FACS Core$206,571
P01 · FY2009 · AI · contact PI
Immunity and Infectious Disease$177,080
T32 · FY2009 · AI · contact PI
Administrative$151,192
P01 · FY2009 · AI · contact PI
Cellular dynamics in germinal centers during vaccination$35,000
R01 · FY2009 · AI · contact PI
ACTIVATION INDUCED DEAMINASE (AID) INTERACTING PROTEINS$2,367
P41 · FY2009 · RR · contact PI
Human Antibody Tolerance in Normal and SLE$485,626
P50 · FY2008 · AR · contact PI
Cellular dynamics in germinal centers during vaccination$426,936
R01 · FY2008 · AI · contact PI
Regulators of Receptor Editing in Developing B Cells$392,994
R01 · FY2008 · AI · contact PI
Targeting Dendritic cells for immune tolerance$331,963
P01 · FY2008 · AI · contact PI
Protein Expression$207,214
P01 · FY2008 · AI · contact PI
Immunity and Infectious Disease$88,100
T32 · FY2008 · AI · contact PI
ACTIVATION INDUCED DEAMINASE (AID) INTERACTING PROTEINS$2,218
P41 · FY2008 · RR · contact PI
Cellular dynamics in germinal centers during vaccination$439,750
R01 · FY2007 · AI · contact PI
Regulators of Receptor Editing in Developing B Cells$400,606
R01 · FY2007 · AI · contact PI
Human Antibody Tolerance in Normal and SLE$400,534
P50 · FY2007 · AR · contact PI
Targeting Dendritic cells for immune tolerance$326,318
P01 · FY2007 · AI · contact PI
Protein Expression$251,742
P01 · FY2007 · AI · contact PI
"ACTIVATION INDUCED DEAMINASE" (AID) INTERACTING PROTEINS$1,883
P41 · FY2007 · RR · contact PI
Regulators of Receptor Editing in Developing B Cells$412,571
R01 · FY2006 · AI · contact PI
Human Antibody Tolerance in Normal and SLE$351,997
P50 · FY2006 · AR · contact PI
"ACTIVATION INDUCED DEAMINASE" (AID) INTERACTING PROTEINS$1,233
P41 · FY2006 · RR · contact PI
Regulators of Receptor Editing in Developing B Cells$422,500
R01 · FY2005 · AI
"ACTIVATION INDUCED DEAMINASE" (AID) INTERACTING PROTEINS$1,190
P41 · FY2005 · RR
Regulators of Receptor Editing in Developing B Cells$421,250
R01 · FY2004 · AI
"ACTIVATION INDUCED DEAMINASE" (AID) INTERACTING PROTEINS$1,178
P41 · FY2004 · RR
SIGNALING PATHWAYS IN AUTOIMMUNITY$320,132
R01 · FY2003 · AI
SIGNALING PATHWAYS IN AUTOIMMUNITY$310,809
R01 · FY2002 · AI
SIGNAL TRANSDUCTION BY IGM IN B LYMPHOCYTES$200,041
R01 · FY2002 · AI
Antigen Targeting to Dendritic Cell$0
P01 · FY2002 · AI
SIGNALING PATHWAYS IN AUTOIMMUNITY$301,756
R01 · FY2001 · AI
SIGNAL TRANSDUCTION BY IGM IN B LYMPHOCYTES$194,213
R01 · FY2001 · AI
SIGNALING PATHWAYS IN AUTOIMMUNITY$292,966
R01 · FY2000 · AI
SIGNAL TRANSDUCTION BY IGM IN B LYMPHOCYTES$188,559
R01 · FY2000 · AI